nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00488878,Data Collection for Patients With Low Grade Ovarian Carcinoma,,Recruiting,Observational,Low Grade Ovarian Serous Adenocarcinoma; Malignant Ovarian Neoplasm; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Low Grade Serous Adenocarcinoma; Psammocarcinoma,Biospecimen Collection; Electronic Health Record Review,,M.D. Anderson Cancer Center,,2000,2006-05-19,2035-05-01,United States,No,https://clinicaltrials.gov/study/NCT00488878
NCT00823654,Multi-Center Study of Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer BRCA Mutations,,Recruiting,Observational,Breast Cancer,Blood draw and questionnaires; Blood draw and questionnaires,,Memorial Sloan Kettering Cancer Center,Yale University; New York Presbyterian Hospital; Weill Medical College of Cornell University,609,2009-01-05,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT00823654
NCT00929006,Study to Assess Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism,Early Phase 1,Recruiting,Interventional,Puberty; Hyperandrogenism,Micronized progesterone suspension; Placebo,,University of Virginia,National Institutes of Health (NIH),36,2008-06-05,2025-12-01,United States,No,https://clinicaltrials.gov/study/NCT00929006
NCT01102569,Molecular Genetics and Epidemiology of Pancreatic Cancer in Ashkenazi Jewish Patients,,Recruiting,Observational,Pancreatic Cancer,,,Columbia University,,100,2008-01-05,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT01102569
NCT01441089,Collection of Blood From Therapeutic Trial Participants for Analysis of Genetic Differences in Drug Disposition and Pharmacokinetics of Probe Medications,,Recruiting,Observational,Prostate Cancer; Breast Cancer; Lung Cancer; Ovarian Cancer; Lymphoma,,,National Cancer Institute (NCI),,1100,2012-05-21,,United States,No,https://clinicaltrials.gov/study/NCT01441089
NCT01870752,Autologous Orthotopic Transplantation of Previously Cryopreserved Ovarian Tissue,Not Applicable,Recruiting,Interventional,Infertile Females or Females With Ovarian Insufficiency,Transplantation of previously cryopreserved ovarian tissu,,Abramson Cancer Center at Penn Medicine,,10,2013-06-05,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT01870752
NCT01970696,International Ovarian & Testicular Stromal Tumor Registry,,Recruiting,Observational,Ovarian Sex-cord Stromal Tumor; Testicular Stromal Tumors; Ovarian Small Cell Carcinoma,,,Children's Hospitals and Clinics of Minnesota,"Children's National Research Institute; Dana-Farber Cancer Institute; Washington University School of Medicine; University of Texas Southwestern Medical Center; M.D. Anderson Cancer Center; Children's Hospital Colorado; Rutgers University; Massachusetts General Hospital; Klinikum Dortmund Wirbelsäulenchirurgie; ResourcePath, LLC; Allina Health System; Phoenix Children's Hospital; University of Cambridge",300,2011-12-08,2030-12-05,United States,No,https://clinicaltrials.gov/study/NCT01970696
NCT02000089,The Cancer of the Pancreas Screening-5 CAPS5)Study,Phase 3,Recruiting,Interventional,Pancreas Cancer; Peutz-Jeghers Syndrome (PJS); Gene Mutation; Germline Mutation Carrier; Lynch Syndrome,Secretin; MRI; Tumor marker gene test with CA19-9,,Johns Hopkins University,National Cancer Institute (NCI); National Institutes of Health (NIH); American Association for Cancer Research,9000,2014-01-06,2029-06-05,United States,No,https://clinicaltrials.gov/study/NCT02000089
NCT02288676,DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics,,Recruiting,Observational,Ovarian Neoplasms; Endometrial Neoplasms; Endometrial Cancer; Ovarian Cancer; Screening; Safety; Reduced Mortality; Reduced Morbidity; Early Diagnosis,,,McGill University,McGill University Health Centre/Research Institute of the McGill University Health Centre,1200,2014-01-05,2026-10-05,Canada,No,https://clinicaltrials.gov/study/NCT02288676
NCT02296307,Diagnosing Ovarian & Endometrial Cancer Early (DOvEE) by Targeting Symptomatic Women,,Recruiting,Observational,Ovarian Neoplasms,Blood test: CA-125 biomarker; Second Test: Transvaginal Ultrasound; Follow-up phone call,,McGill University,,13600,2012-01-05,2026-01-05,Canada,No,https://clinicaltrials.gov/study/NCT02296307
NCT02302742,"PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations",,Recruiting,Observational,Breast Cancer; Hereditary Breast and Ovarian Cancer,,,University of Kansas Medical Center,,1500,2011-03-22,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT02302742
NCT02333604,Cancer Experience Registry: An Online Survey Research Study to Understand the Experiences of Cancer Patients and Caregivers,,Recruiting,Observational,Neoplasms; Cancer; Caregiver,,,"Cancer Support Community, Research and Training Institute, Philadelphia",,15000,2013-03-05,2035-12-05,United States,No,https://clinicaltrials.gov/study/NCT02333604
NCT02693535,Targeted Agent and Profiling Utilization Registry (TAPUR) Study,Phase 2,Recruiting,Interventional,"Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors",Palbociclib; Sunitinib; Temsirolimus; Trastuzumab and Pertuzumab; Vemurafenib and Cobimetinib; Regorafenib; Olaparib; Pembrolizumab; Nivolumab and Ipilimumab; Abemaciclib; Talazoparib; Atezolizumab and PHESGO; Atezolizumab and Talazoparib; Entrectinib; Larotrectinib; Tucatinib plus Trastuzumab Subcutaneous (SC); Futibatinib,,American Society of Clinical Oncology,"AstraZeneca; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Merck Sharp & Dohme LLC; Pfizer; Boehringer Ingelheim; Seagen Inc.; Taiho Oncology, Inc.",4200,2016-03-14,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT02693535
NCT02732860,Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host,,Recruiting,Observational,Colorectal Neoplasms; Colorectal Cancer; Breast Cancer; Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasm,Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures,,"University Health Network, Toronto",,120,2015-12-05,2026-01-04,Canada,No,https://clinicaltrials.gov/study/NCT02732860
NCT02775461,Pancreas Disease and High Risk Registry,,Recruiting,Observational,Pancreas Cancer; Pancreatitis; Chronic Pancreatitis; Pancreatic Cyst; Family History of Pancreas Cancer; Genetic Mutations,,,Icahn School of Medicine at Mount Sinai,,1116,2013-03-01,2033-11-05,United States,No,https://clinicaltrials.gov/study/NCT02775461
NCT03419689,Biomarker Discovery Project in High Grade Serous Ovarian Cancer,Not Applicable,Recruiting,Interventional,Gynecologic Cancer,Tumour tissue collection; Blood sample collection; Ascites Collection; Fluid Collection,,"University Health Network, Toronto",,510,2018-01-08,2028-06-08,Canada,No,https://clinicaltrials.gov/study/NCT03419689
NCT03428802,A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability,Phase 2,Recruiting,Interventional,BRCA1 Gene Mutation; BRCA2 Gene Mutation; Locally Advanced Solid Neoplasm; Metastatic Malignant Solid Neoplasm; POLD1 Gene Mutation; POLE Gene Mutation; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Stage III Breast Cancer AJCC v7; Stage III Ovarian Cancer AJCC v8; Stage IIIA Breast Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIB Breast Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIC Breast Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v8; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8,Laboratory Biomarker Analysis; Pembrolizumab,,"Rutgers, The State University of New Jersey",National Cancer Institute (NCI),40,2018-03-08,2023-10-02,United States,No,https://clinicaltrials.gov/study/NCT03428802
NCT03544983,A Randomized Trial of Proactive Outreach and Streamlined Genetic Education in BRCA Families,Not Applicable,Enrolling by invitation,Interventional,BRCA1 Mutation; BRCA2 Mutation,Web + Streamlined Telephone Genetic Information,,Georgetown University,George Washington University,240,2020-05-01,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT03544983
NCT03564340,"A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers",Phase 1/Phase 2,Recruiting,Interventional,Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer; Recurrent Endometrial Cancer; Endometrial Cancer; Low-grade Serous Ovarian Cancer,Ubamatamab; Cemiplimab; Sarilumab; Tocilizumab,,Regeneron Pharmaceuticals,,890,2018-05-21,2027-01-31,Australia; Belgium; France; Israel; Italy; Netherlands; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT03564340
NCT03568630,A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer,,Recruiting,Observational,"Diabetes Mellitus, Type 2; PreDiabetes; Pancreas Cyst; Chronic Pancreatitis; Genetic Predisposition to Disease; Inherited Disease",,,University of Nebraska,National Cancer Institute (NCI); Virginia Mason Hospital/Medical Center; VA Nebraska Western Iowa Health Care System,1250,2018-07-26,2028-07-05,United States,No,https://clinicaltrials.gov/study/NCT03568630
NCT03702309,Liquid Biopsy Evaluation and Repository Development at Princess Margaret,,Recruiting,Observational,Cancer; Breast Cancer; Lung Cancer; Colon Cancer; Ovarian Cancer; Melanoma; Lymphoma; Leukemia; Mutation; Lynch Syndrome; Cowden Syndrome; BRCA1 Mutation; BRCA2 Mutation; Uterine Cancer; Myeloma; Kidney Cancer; Head and Neck Cancer; Meningioma,,,"University Health Network, Toronto",,2500,2017-08-03,2026-07-06,Canada,No,https://clinicaltrials.gov/study/NCT03702309
NCT03772028,Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy,Phase 3,Recruiting,Interventional,Ovarian Cancer,cisplatin,,The Netherlands Cancer Institute,,538,2020-01-01,2026-04-01,Denmark; France; Ireland; Italy; Netherlands; Sweden; United States,No,https://clinicaltrials.gov/study/NCT03772028
NCT04038502,"An Open-label, Multicenter Phase II Study to Compare the Efficacy of Carboplatin as First-line Followed by Second-line Olaparib Versus Olaparib as First-line Followed by Second-line Carboplatin in the Treatment of Patients With Castration Resistant Prostate Cancer Containing Homologous Recombination Deficiency",Phase 2,Recruiting,Interventional,"Metastatic Castrate Resistant Prostate Cancer; BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2; RAD51B, RAD51C, RAD51D, or RAD54L Mutations",Carboplatin; Olaparib,,VA Office of Research and Development,,100,2019-10-01,2027-08-31,United States,No,https://clinicaltrials.gov/study/NCT04038502
NCT04090567,Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer,Phase 2,Recruiting,Interventional,Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Cediranib; Ceralasertib; Olaparib,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),60,2020-07-28,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT04090567
NCT04251052,A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk],Not Applicable,Recruiting,Interventional,Ovarian Carcinoma,Bilateral Salpingectomy; Bilateral Salpingectomy with Oophorectomy; Biospecimen Collection; Magnetic Resonance Imaging; Quality-of-Life Assessment; Questionnaire Administration; Transvaginal Ultrasound; Ultrasound Imaging,,NRG Oncology,National Cancer Institute (NCI),1956,2020-09-01,2047-06-30,Canada; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04251052
NCT04254133,Genetic Information to Inform Treatment and Screening (GIFTS) Study for Prostate Cancer,,Enrolling by invitation,Observational,Prostate Carcinoma,Questionnaire; Biospecimen Collection; Genetic Testing; Genetic Counseling; Laboratory Biomarker Analysis,,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),1360,2018-11-30,2028-08-31,United States,No,https://clinicaltrials.gov/study/NCT04254133
NCT04258449,DOvEEgene Fleur: New Uterine Sampling Tool,,Recruiting,Observational,Women With Suspected or Confirmed Gynecological Disease,DOvEEgene Fleur Sampling,,McGill University,McGill University Health Centre/Research Institute of the McGill University Health Centre; GSE Biomedical,40,2020-12-11,2026-10-01,Canada,No,https://clinicaltrials.gov/study/NCT04258449
NCT04294927,TUBectomy With Delayed Oophorectomy as Alternative for Risk-reducing Salpingo-oophorectomy in High Risk Women to Assess the Safety of Prevention: TUBA-WISP II Study.,Not Applicable,Recruiting,Interventional,BRCA1 Gene Mutation; BRCA2 Gene Mutation; RAD51C Gene Mutation; RAD51D Gene Mutation; BRIP1 Gene Mutation; Ovarian Cancer,Risk-reducing salpingectomy with delayed oophorectomy; Risk-reducing salpingo-oophorectomy,,University Medical Center Nijmegen,,3000,2020-03-01,2040-02-17,Australia; Belgium; Brazil; Italy; Mexico; Netherlands; Norway; Poland; Sweden; United States; Uruguay,No,https://clinicaltrials.gov/study/NCT04294927
NCT04300556,"A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,Farletuzumab ecteribulin; Prednisone; Prednisolone; Dexamethasone; Lenvatinib,,Eisai Inc.,,182,2020-08-06,2030-08-08,France; Japan; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04300556
NCT04314401,Cancer Moonshot Biobank Research Protocol,,Recruiting,Observational,Acute Myeloid Leukemia; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Carcinoma; Fallopian Tube Carcinoma; Gastric Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Invasive Breast Carcinoma; Lung Non-Small Cell Carcinoma; Lung Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Metastatic Prostate Carcinoma; Multiple Myeloma; Ovarian Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Triple-Negative Breast Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Medical Chart Review; Paracentesis; Positron Emission Tomography,,National Cancer Institute (NCI),,1600,2020-11-11,2027-04-30,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04314401
NCT04389632,A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors,Phase 1,Recruiting,Interventional,"Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck; HER2 Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Ovarian Neoplasms; Cutaneous Squamous Cell Cancer; Exocrine Pancreatic Adenocarcinoma; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Stomach Neoplasms",sigvotatug vedotin; pembrolizumab; cisplatin; carboplatin,,"Seagen, a wholly owned subsidiary of Pfizer",,1006,2020-06-08,2029-03-22,France; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04389632
NCT04431024,"Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome",,Recruiting,Observational,Familial Cancer; BRCA1-Associated Protein-1 (BAP1) Mutations; Tumor Predisposition Syndrome (TPDS); Mesothelioma,,,National Cancer Institute (NCI),,800,2021-03-30,2038-06-30,United States,No,https://clinicaltrials.gov/study/NCT04431024
NCT04585958,A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies,Phase 1,Recruiting,Interventional,Metastatic Malignant Solid Neoplasm; Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma; Unresectable Malignant Solid Neoplasm,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test; Multigated Acquisition Scan; Olaparib; Trastuzumab Deruxtecan,,National Cancer Institute (NCI),,55,2021-05-21,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04585958
NCT04633239,A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer,Phase 1,Recruiting,Interventional,Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma,Abemaciclib; Biopsy Procedure; Biospecimen Collection; Olaparib,,National Cancer Institute (NCI),,42,2021-07-02,2026-11-01,United States,No,https://clinicaltrials.gov/study/NCT04633239
NCT04657068,"A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer; Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; Metastatic Colorectal Cancer; Pancreatic Ductal Adenocarcinoma; Acinar Cell Carcinoma,ART0380; Gemcitabine; Irinotecan,,Artios Pharma Ltd,,502,2020-12-13,2026-12-05,France; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04657068
NCT04752826,"Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 As a Single Agent and in Combination with Pembrolizumab (MK-3475-D20) in Subjects with Advanced Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Advanced Malignancies; Ovarian Cancer; T-cell Lymphoma; Melanoma,BI-1808; Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection,,BioInvent International AB,Merck Sharp & Dohme LLC,176,2021-01-25,2028-01-15,Denmark; Hungary; Russia; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04752826
NCT04787289,A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer - a Pragmatic Trial,Phase 2,Recruiting,Interventional,Ovarian Cancer; Platinum-resistant Ovarian Cancer,Bevacizumab,,British Columbia Cancer Agency,,244,2021-09-10,2025-01-31,Canada,No,https://clinicaltrials.gov/study/NCT04787289
NCT04794322,Ovarian Cancer Detection by Uterine Lavage DNA and Serum Proteins: a Phase 2 Biomarker Study,,Recruiting,Observational,Ovarian Neoplasms; Ovarian Epithelial Carcinoma; Fallopian Tube Neoplasms; High Grade Ovarian Serous Adenocarcinoma; Stage I Ovarian Cancer; Stage II Ovarian Cancer; Stage III Ovarian Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8,"Uterine lavage, or a wash of the womb; Blood sample; Pap smear",,Massachusetts General Hospital,Johns Hopkins University; Fred Hutchinson Cancer Center; Anne Arundel Health System Research Institute; University of Arkansas; National Cancer Institute (NCI); Kaiser Permanente; McGill University; M.D. Anderson Cancer Center; Swedish Medical Center; Early Detection Research Network,250,2020-04-13,2028-08-31,United States,No,https://clinicaltrials.gov/study/NCT04794322
NCT04858334,"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",Phase 2,Recruiting,Interventional,Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib; Placebo Administration,,National Cancer Institute (NCI),,152,2021-06-22,2027-10-31,Israel; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04858334
NCT04890613,Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation,Phase 1,Recruiting,Interventional,Advanced Solid Tumor,CX-5461,,"Senhwa Biosciences, Inc.",,52,2021-09-08,2026-12-05,Canada; United States,No,https://clinicaltrials.gov/study/NCT04890613
NCT04918186,An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer,Phase 2,Recruiting,Interventional,Ovarian Cancer,Durvalumab; BA3011; BA3021; ENB003; Toripalimab,,Canadian Cancer Trials Group,"Cancer Research Institute, New York City; AstraZeneca; BioAtla, Inc.",60,2022-05-03,2026-12-31,Canada; United States,No,https://clinicaltrials.gov/study/NCT04918186
NCT04969835,"A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours",Phase 1,Recruiting,Interventional,Salivary Gland Tumor; Urothelial Carcinoma; Ovarian Carcinoma; Breast Cancer; Soft Tissue Sarcoma,AVA6000,,Avacta Life Sciences Ltd,,158,2021-07-16,2026-08-15,United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04969835
NCT04970056,Pancreatic Cancer Early Detection Consortium,,Recruiting,Observational,Pancreas Cancer; Pancreas Cyst; Pancreatic Ductal Adenocarcinoma; Genetic Predisposition,,,Arbor Research Collaborative for Health,,10000,2020-09-18,2030-12-31,Australia; Canada; Hungary; Iceland; Israel; Italy; Singapore; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04970056
NCT04995198,PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness,,Recruiting,Observational,Prostate Cancer,,,Prostate Cancer Clinical Trials Consortium,"Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Advancing Cancer Treatment, Inc.",500,2021-05-03,2036-02-26,United States,No,https://clinicaltrials.gov/study/NCT04995198
NCT05005403,"A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Micro Satellite Stable Colorectal Cancer; Gastric/Esophageal Cancer; High-Grade Serous Ovarian Cancer; Pancreatic Cancer; Triple Negative Breast Cancer,Azirkitug; Budigalimab; Bevacizumab,,AbbVie,,512,2021-11-01,2027-06-05,Israel; Japan; South Korea; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT05005403
NCT05039801,"A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Endometrial Carcinoma; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Clear Cell Adenocarcinoma; Chondrosarcoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Recurrent Ovarian High Grade Serous Adenocarcinoma; Refractory Endometrial Carcinoma; Refractory Head and Neck Squamous Cell Carcinoma; Refractory Melanoma; Refractory Ovarian Clear Cell Adenocarcinoma; Refractory Ovarian High Grade Serous Adenocarcinoma; Stage III Ovarian Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Bevacizumab; Glutaminase-1 Inhibitor IACS-6274; Paclitaxel; Capivasertib,,M.D. Anderson Cancer Center,,54,2021-09-09,2026-05-29,United States,No,https://clinicaltrials.gov/study/NCT05039801
NCT05065021,Re-VOLVE: A Phase II Clinical Trial in Women With Ovarian Cancer Progressing Post-PARP Inhibitor With Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance,Phase 2,Recruiting,Interventional,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High Grade Serous Cancer; High Grade Endometrioid Cancer,Niraparib; Dostarlimab; Bevacizumab; Paclitaxel,,"University Health Network, Toronto",GlaxoSmithKline,40,2023-02-23,2025-06-06,Canada,No,https://clinicaltrials.gov/study/NCT05065021
NCT05128825,"A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)",Phase 2,Recruiting,Interventional,"High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer",azenosertib,,"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",,170,2022-02-17,2027-06-30,Australia; Belgium; France; Italy; Poland; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05128825
NCT05129605,Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS),,Recruiting,Observational,Prostatic Neoplasm; Prostate Cancer; BRCA2 Mutation; BRCA1 Mutation; ATM Gene Mutation; MMR Mutation; Lynch Syndrome; Genetic Predisposition to Disease,Prostate cancer screening,,Massachusetts General Hospital,,400,2020-02-12,2040-12-05,United States,No,https://clinicaltrials.gov/study/NCT05129605
NCT05142033,Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer (ASAP Study),,Recruiting,Observational,Cancer; Cancer Diagnosis; Early Detection of Cancer; Breast Cancer; Lung Cancer; Colon Cancer; GI Cancer; Gynecologic Cancer; Ovarian Cancer; Endometrial Cancer; CNS Cancer; Hematologic Cancer,,,Avera McKennan Hospital & University Health Center,,25000,2021-11-01,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT05142033
NCT05277051,"A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Neoplasms,Remzistotug; Dostarlimab; Belrestotug; Nelistotug; GSK5764227,,GlaxoSmithKline,,158,2022-03-22,2027-08-31,Australia; Canada; China; France; Japan; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05277051
NCT05281471,"A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)",Phase 3,Recruiting,Interventional,Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma,"olvimulogene nanivacirepvec; Platinum chemotherapy: carboplatin (preferred) or cisplatin; Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin; Bevacizumab (or biosimilar)",,Genelux Corporation,GOG Foundation,186,2022-08-31,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT05281471
NCT05287451,Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study,Not Applicable,Recruiting,Interventional,Ovarian Cancer; Fallopian Tube Cancer,RIsk-Reducing Salpingectomy (RRS); Risk-Reducing Oophorectomy-RRO; Risk-Reducing Salpingo-Oophorectomy-RRSO,,M.D. Anderson Cancer Center,,100,2022-05-10,2026-12-26,United States,No,https://clinicaltrials.gov/study/NCT05287451
NCT05300711,"Preventing Ovarian Cancer Through the Expansion of Opportunistic Salpingectomy: Uptake, Safety and Cost-effectiveness at the Time of Colorectal Surgery",Not Applicable,Recruiting,Interventional,Salpingectomy; Colorectal Surgery,Bilateral salpingectomy; Colorectal surgery,,University of British Columbia,Canadian Cancer Society (CCS); Canadian Institutes of Health Research (CIHR),240,2022-06-20,2026-03-05,Canada,No,https://clinicaltrials.gov/study/NCT05300711
NCT05309746,Ovarian Tissue Cryopreservation for Fertility Preservation in Post-Pubertal Children Facing a Fertility Threatening Diagnosis or Treatment Regimen,,Recruiting,Observational,Pediatric Cancer,Laparoscopic surgery,,Erin Rowell,,250,2017-11-01,2035-01-05,United States,No,https://clinicaltrials.gov/study/NCT05309746
NCT05327010,"Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)",Phase 2,Recruiting,Interventional,Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm,BET Bromodomain Inhibitor ZEN-3694; Biopsy Procedure; Biospecimen Collection; Diagnostic Imaging Testing; Talazoparib,,National Cancer Institute (NCI),,88,2022-11-14,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT05327010
NCT05429970,Perioperative Stress Reduction in Ovarian Cancer (PRESERVE Trial)-A Prospective Randomized Pilot Study,Not Applicable,Recruiting,Interventional,Ovarian Cancer; Ovarian Carcinoma; Stage II Ovary Cancer; Stage II Ovarian Cancer; Stage III Ovary Cancer; Stage III Ovarian Cancer; Stage IV Ovary Cancer; Stage IV Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Stage II Fallopian Tube Cancer; Stage III Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Primary Peritoneal Carcinoma,Mind-body resilience training; Music therapy; Propranolol; Etodolac,,Memorial Sloan Kettering Cancer Center,,35,2022-06-17,2026-06-17,United States,No,https://clinicaltrials.gov/study/NCT05429970
NCT05498272,A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune),Phase 2,Recruiting,Interventional,Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer,Olaparib; LHRH agonist,,"Rana McKay, MD","AstraZeneca; University of California, San Diego",32,2023-02-01,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05498272
NCT05512208,A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK),Phase 2,Recruiting,Interventional,Endometrioid Cancer; Mucinous Ovarian Cancer; High Grade Serous Ovarian Cancer; Cervical Cancer; Solid Tumor,Avutometinib (VS-6766) + defactinib,,University of Oklahoma,"Verastem, Inc.",55,2023-02-06,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT05512208
NCT05527184,"A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers",Phase 1,Recruiting,Interventional,Endometrial Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Cervical Cancer,IMGN151,,AbbVie,,423,2023-01-11,2027-02-05,Australia; Belgium; Canada; France; Germany; Ireland; Italy; Netherlands; Spain; United States,No,https://clinicaltrials.gov/study/NCT05527184
NCT05579366,Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC); Mesothelioma; Breast Adenocarcinoma; Triple Negative Breast Cancer; Hormone Receptor-positive/Her2 Negative Breast Cancer; Platinum-resistant Ovarian Cancer (PROC); Platinum Sensitive Ovarian Cancer (PSOC); Primary Refractory Ovarian Cancer; Uterine Cancer,Rina-S; Carboplatin; Bevacizumab; Pembrolizumab,,Genmab,,764,2022-12-07,2027-10-05,China; Japan; United States,No,https://clinicaltrials.gov/study/NCT05579366
NCT05625529,Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients,,Recruiting,Observational,Pancreas Cancer; Exosomes; Extracellular Vesicles; Pancreatic Neoplasms,,,Biological Dynamics,,1000,2022-12-19,2028-01-01,United States,No,https://clinicaltrials.gov/study/NCT05625529
NCT05694715,Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes,Phase 1,Recruiting,Interventional,Metastatic Solid Tumor; BRCA1 Mutation; BRCA2 Mutation; ATM Gene Mutation; PALB2 Gene Mutation,Niraparib; Irinotecan,,"University of California, San Francisco",GlaxoSmithKline,24,2023-05-23,2028-01-31,United States,No,https://clinicaltrials.gov/study/NCT05694715
NCT05720117,"A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Solid Tumor,PYX-201,,"Pyxis Oncology, Inc",,330,2023-03-14,2027-05-05,Belgium; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05720117
NCT05746897,"A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Ovarian Cancer; Melanoma; Triple Negative Breast Cancer; Colorectal Cancer,NM1F Injection; Pembrolizumab injection,,"Hefei TG ImmunoPharma Co., Ltd.",,38,2023-04-13,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT05746897
NCT05752448,POSTCARE-O: Survivorship Care for Women Living With Ovarian Cancer,Not Applicable,Recruiting,Interventional,Ovarian Neoplasm; Depressive Symptoms; Quality of Life,POSTCare Survivorship transition process,,Baylor College of Medicine,"Cancer Prevention Research Institute of Texas; The University of Texas Health Science Center, Houston; University of Texas Southwestern Medical Center; University of Texas at Austin",120,2023-10-01,2027-04-15,United States,No,https://clinicaltrials.gov/study/NCT05752448
NCT05787587,A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors,Phase 1,Recruiting,Interventional,Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Endometrial Cancer; Colorectal Cancer; Head and Neck Cancers; Extensive Stage Small Cell Lung Cancer (ES-SCLC); NSCLC,IDE-161; Pembrolizumab,,IDEAYA Biosciences,Merck Sharp & Dohme LLC,216,2023-04-05,2027-05-05,United States,No,https://clinicaltrials.gov/study/NCT05787587
NCT05806515,"S2210 A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer With Germline BRCA1/2 Mutations",Phase 2,Recruiting,Interventional,Prostate Adenocarcinoma; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8,Biospecimen Collection; Carboplatin; Chest Radiography; Computed Tomography; Magnetic Resonance Imaging; PSMA PET Scan; Surgical Procedure,,SWOG Cancer Research Network,National Cancer Institute (NCI),44,2024-03-01,2031-06-05,United States,No,https://clinicaltrials.gov/study/NCT05806515
NCT05827614,"An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications",Phase 1,Recruiting,Interventional,Triple Negative Breast Cancer (TNBC); High Grade Serous Ovarian Carcinoma; High Grade Endometrial Carcinoma; Anogenital Cancer; Head and Neck (HNSCC); Cutaneous Squamous Cell Carcinoma (CSCC); Cervical Squamous Cell Carcinoma; ER+ Breast Cancer; Leiomyosarcoma (LMS); Undifferentiated Pleomorphic Sarcoma (UPS); Pancreatic Cancer Metastatic; Small Cell Lung Cancer,BBI-355; Erlotinib; Futibatinib; BBI-825,,Boundless Bio,,127,2023-03-24,2027-03-31,United States,No,https://clinicaltrials.gov/study/NCT05827614
NCT05879926,"A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)",Phase 3,Recruiting,Interventional,Breast Cancer,Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression,,NRG Oncology,National Cancer Institute (NCI),3960,2023-08-31,2034-07-05,Canada; Colombia; Japan; Mexico; Peru; Puerto Rico; United States; Uruguay,No,https://clinicaltrials.gov/study/NCT05879926
NCT05902988,A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer,Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancer; Triple Negative Breast Cancer; Head and Neck Squamous Cell Carcinoma; Ovarian Carcinosarcoma; Uterine Carcinosarcoma; Uterine Serous Carcinoma; Endometrium Cancer; Chromosomal Instability,VLS-1488,,"Volastra Therapeutics, Inc.",,200,2023-10-18,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05902988
NCT05920798,"MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)",Phase 1/Phase 2,Recruiting,Interventional,Fallopian Tube Carcinosarcoma; Primary Peritoneal Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Fallopian Tube Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Carcinosarcoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Clear Cell Adenocarcinoma; Recurrent Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Carcinosarcoma,Biopsy; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine; Pembrolizumab; Pheresis,,Mayo Clinic,NanoPass Technologies Ltd; National Cancer Institute (NCI),40,2023-09-28,2027-07-15,United States,No,https://clinicaltrials.gov/study/NCT05920798
NCT05950282,"Measuring Fasting Insulin and HOMA-IR by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis",,Recruiting,Observational,Insulin Resistance; Polycystic Ovary Syndrome; Hyperinsulinism; Obesity; Metabolic Syndrome,,,Lilli Health,,500,2024-02-01,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05950282
NCT05950464,A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer,Phase 1,Recruiting,Interventional,Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma,BET Bromodomain Inhibitor ZEN-3694; Biopsy Procedure; Biospecimen Collection; Computed Tomography; Electrocardiography; Magnetic Resonance Imaging; Tuvusertib; X-Ray Imaging,,National Cancer Institute (NCI),NRG Oncology,60,2023-12-18,2026-04-30,United States,No,https://clinicaltrials.gov/study/NCT05950464
NCT05961124,"A Phase II, Single-Arm Trial Assessing Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer: Dose Escalation",Phase 2,Recruiting,Interventional,Ovarian Cancer; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; High Grade Ovarian Serous Adenocarcinoma,Niraparib,,Sunnybrook Health Sciences Centre,GlaxoSmithKline,40,2023-08-21,2027-09-05,Canada,No,https://clinicaltrials.gov/study/NCT05961124
NCT05989724,"A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Participants With Relapsed/Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumor; Breast Cancer; Pancreatic Cancer; Ovarian Cancer; Colorectal Cancer,SON-DP,,Qurgen Inc.,,150,2023-09-19,2026-03-05,United States,No,https://clinicaltrials.gov/study/NCT05989724
NCT05998135,Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer,Phase 2,Recruiting,Interventional,Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Ovarian Carcinoma,Atovaquone; Biopsy; Computed Tomography; Paracentesis,,Emory University,National Cancer Institute (NCI),28,2023-11-09,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT05998135
NCT06083844,Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy,Phase 2,Recruiting,Interventional,Ovarian Cancer,Pembrolizumab; Bevacizumab; Cyclophosphamide,,M.D. Anderson Cancer Center,,20,2023-12-12,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT06083844
NCT06108479,"A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors",Phase 1,Recruiting,Interventional,"Solid Tumor, Adult; Solid Tumor Cancer",DF6215; pembrolizumab; KEYTRUDA®,,Dragonfly Therapeutics,Merck Sharp & Dohme LLC,255,2023-11-28,2027-12-05,Australia; France; United States,No,https://clinicaltrials.gov/study/NCT06108479
NCT06151223,A Prospective Registry for Patients at High-Risk for Pancreatic Cancer,,Recruiting,Observational,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,Bio-specimen Collection: Blood; Bio-specimen Collection: Pancreatic Juice; MRI,,Mayo Clinic,,5000,2021-07-13,2031-07-31,United States,No,https://clinicaltrials.gov/study/NCT06151223
NCT06177171,A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors,Phase 1,Recruiting,Interventional,BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; PALB2 Gene Mutation; Checkpoint Kinase 2 Gene Mutation; ATM Gene Mutation,Olaparib; ASTX727,,Pamela Munster,National Cancer Institute (NCI),18,2024-02-07,2027-02-28,United States,No,https://clinicaltrials.gov/study/NCT06177171
NCT06188520,"A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC),AZD8421; Camizestrant; Ribociclib; Palbociclib; Abemaciclib,,AstraZeneca,,348,2023-12-05,2026-06-17,Australia; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06188520
NCT06257264,"A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Breast Cancer; Small Cell Lung Cancer; Ovarian Cancer; Gastric Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced Solid Tumor; Endometrial Cancer; Prostate Cancer; TNBC - Triple-Negative Breast Cancer; GastroEsophageal Cancer; Bladder Cancer,BG-68501; Fulvestrant; BGB-43395,,BeiGene,,258,2024-03-11,2028-07-05,Australia; China; Israel; Moldova; New Zealand; United States,No,https://clinicaltrials.gov/study/NCT06257264
NCT06315491,A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer,Phase 2,Recruiting,Interventional,Platinum-resistant Ovarian Cancer; Refractory Ovarian Carcinoma,CBX-12,,Cybrexa Therapeutics,,40,2024-09-25,2025-10-05,United States,No,https://clinicaltrials.gov/study/NCT06315491
NCT06395519,A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies,Phase 1/Phase 2,Recruiting,Interventional,Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarian Cancer; BRCA2 Mutation; ER+ Breast Cancer; Castrate Resistant Prostate Cancer; BRCA1 Mutation; BRCA Mutation; Endometrial Cancer; Colorectal Cancer; Gastric Cancer,ETX-19477,,"858 Therapeutics, Inc.",,120,2024-05-13,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT06395519
NCT06400472,"A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors",Phase 1,Recruiting,Interventional,"Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Neoplasms; Pancreatic Neoplasm; Colorectal Neoplasms",LY4170156; bevacizumab; carboplatin; Itraconazole; pembrolizumab,,Eli Lilly and Company,,495,2024-05-20,2027-04-05,Australia; France; Italy; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06400472
NCT06451497,"Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Pembrolizumab in Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Non Small Cell Lung Cancer; Esophageal Cancer; Head and Neck Squamous Cell Carcinoma; Pancreas Adenocarcinoma; Biliary Tract Cancer; Prostate Cancer; Urothelial Carcinoma; Colorectal Cancer; Triple Negative Breast Cancer; High Grade Ovarian Serous Adenocarcinoma; Diffuse Large B Cell Lymphoma,ZM008,,Zumutor Biologics Inc.,,33,2024-05-22,2027-04-05,United States,No,https://clinicaltrials.gov/study/NCT06451497
NCT06459271,A Feasibility Trial of Managing Cancer and Living Meaningfully (CALM) in Patients With Newly Diagnosed and Recurrent Advanced Ovarian Cancer,Not Applicable,Recruiting,Interventional,Patient Satisfaction; Ovarian Cancer,Managing Cancer And Living Meaningfully (CALM),,"University Health Network, Toronto",Canadian Institutes of Health Research (CIHR),50,2024-06-10,2026-08-10,Canada,No,https://clinicaltrials.gov/study/NCT06459271
NCT06476808,A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors,Phase 1,Recruiting,Interventional,High-grade Serous Ovarian Carcinoma (HGSOC); Uterine Serous Carcinoma (USC); Non-small Cell Lung Cancer (NSCLC),BMS-986463,,Bristol-Myers Squibb,,240,2024-09-06,2028-12-19,Canada; France; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06476808
NCT06503146,18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection,Phase 2,Recruiting,Interventional,Sarcoma; Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC); Mesothelioma; Pheochromocytoma/Paraganglioma (PPGL); Pancreatic Ductal Adenocarcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Gastric Cancer; Cholangiocarcinoma; Bladder Cancer,[18F]FAPI-74; [18F]FDG,,National Cancer Institute (NCI),,320,2025-09-09,2030-06-01,United States,No,https://clinicaltrials.gov/study/NCT06503146
NCT06504147,"A Phase 2, Randomised, Open Label, Multicentre Study of an Intraperitoneal Α-emitting Radionuclide Therapy (Radspherin®) in Patients with Primary Advanced High-grade Serous or High-grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, with Peritoneal Metastasis That Are Homologous Recombination Proficient and Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery",Phase 2,Recruiting,Interventional,Peritoneal Carcinomatosis; Ovarian Cancer,Radspherin,,Oncoinvent AS,,114,2024-06-15,2031-02-28,Belgium; Norway; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06504147
NCT06545604,Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer,Not Applicable,Recruiting,Interventional,Ovarian Cancer,"Yoga Therapy for Nutritional, Physical, and Psychosocial Prehabilitation; Usual care supportive services including nutrition counseling per usual care",,M.D. Anderson Cancer Center,,40,2025-06-06,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT06545604
NCT06555744,"A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,ZW191,,Zymeworks BC Inc.,,145,2024-10-30,2027-01-05,Australia; Japan; Singapore; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06555744
NCT06580314,"A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy",Phase 3,Recruiting,Interventional,Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; FIGO Stage III Ovarian Cancer 2014; FIGO Stage IV Ovarian Cancer 2014; Ovarian Carcinoma; Ovarian High Grade Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma,Bevacizumab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib,,NRG Oncology,National Cancer Institute (NCI),880,2025-03-12,2034-12-31,Japan; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06580314
NCT06582017,A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma,Phase 1,Recruiting,Interventional,Ovarian Cancer; Pancreas Cancer; Urothelial Carcinoma; Renal Cell Carcinoma; Hepatocellular Carcinoma; Gastrointestinal Cancer; Lung Cancer; Prostate Cancer; Breast Cancer,QXL138AM Injection every 2 weeks by IV Infusion,,Nammi Therapeutics Inc,,100,2024-08-28,2028-05-30,United States,No,https://clinicaltrials.gov/study/NCT06582017
NCT06617923,A Phase 2 Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer,Phase 2,Recruiting,Interventional,Ovary Cancer; Fallopian Tube Cancer; Primary Peritoneal Cavity Cancer,Senaparib; Temozolomide,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI); Impact Therapeutics,18,2025-02-06,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT06617923
NCT06619236,"A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer",Phase 3,Recruiting,Interventional,Platinum-resistant Ovarian Cancer,Rina-S; Paclitaxel; Topotecan; Pegylated liposomal doxorubicin (PLD); Gemcitabine,,Genmab,,530,2025-02-07,2028-05-23,Australia; Austria; Belgium; Canada; Czechia; Denmark; France; Germany; Greece; Italy; Japan; Netherlands; Norway; Poland; Puerto Rico; Spain; United States,No,https://clinicaltrials.gov/study/NCT06619236
NCT06639074,MC1963 Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients With Advanced Stage Ovarian Cancer: A Phase II Double-Blind Randomized Clinical Trial (FAROUT),Phase 2,Recruiting,Interventional,Advanced Fallopian Tube Carcinoma; Advanced Fallopian Tube High Grade Serous Adenocarcinoma; Advanced Ovarian Carcinoma; Advanced Ovarian Carcinosarcoma; Advanced Ovarian Clear Cell Adenocarcinoma; Advanced Ovarian Endometrioid Adenocarcinoma; Advanced Ovarian High Grade Serous Adenocarcinoma; Advanced Primary Peritoneal Carcinoma; Advanced Primary Peritoneal High Grade Serous Adenocarcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; FIGO Stage III Ovarian Cancer 2014; FIGO Stage IV Ovarian Cancer 2014; Ovarian Mixed Cell Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma,Biopsy; Biospecimen Collection; Computed Tomography; Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed; Leukapheresis; Magnetic Resonance Imaging; Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine; Placebo Administration; Tetanus and Diphtheria Toxoids Adsorbed,,Mayo Clinic,,78,2024-11-08,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT06639074
NCT06654050,Phase II Study of Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma,Phase 2,Not yet recruiting,Interventional,Mesothelioma; Malignant Mesothelioma (MM); Early-stage Mesothelioma; Subclinical Mesothelioma; BRCA1-Associated Protein-1 (BAP1) Mutations; Early-stage BAP1-associated Malignancies,alrizomadlin,,National Cancer Institute (NCI),,15,2026-01-06,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT06654050
NCT06659614,Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease,,Recruiting,Observational,Prostate Cancer; Genetic Predisposition,,,Abramson Cancer Center at Penn Medicine,,200,2024-01-01,2034-01-05,United States,No,https://clinicaltrials.gov/study/NCT06659614
